TABLE 4.

Representative therapeutic antibodies strategies for CoV infections.

Name of drugs	Mechanism of action	In vitro	In vivo	Clinical trial	Approved	References
Meplazumab	Anti-CD147	SARS-CoV-2	SARS-CoV-2	SARS-CoV-2	N.A.	Wang et al., 2020b
P2C-1F11	Competes with ACE2 for binding to SARS-CoV2 RBD	SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Ju et al., 2020; Ge J. et al., 2021
P2C-1A3	Competes with ACE2 for binding to SARS-CoV2 RBD	SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Ju et al., 2020
P2B-2F6	Competes with ACE2 for binding to SARS-CoV2 RBD	SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Ju et al., 2020
47D11	Binds to SARS-CoV and SARS-CoV-2 spike RBD and ectodomain	SARS-CoV, SARS-CoV-2	N.A.	NCT04644120	N.A.	Wang et al., 2020a
CR3022	Binds to RBD	SARS-CoV, SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Yuan et al., 2020; Atyeo et al., 2021
4A8	Binds to NTD	SARS-CoV-2	N.A.	N.A.	N.A.	Chi et al., 2020
H4	Blocks interaction of RBD-ACE2	SARS-CoV-2	N.A.	N.A.	N.A.	Wang et al., 2020d; Wu et al., 2020c
B38	Blocks interaction of RBD-ACE2	SARS-CoV-2	N.A.	N.A.	N.A.	Wang et al., 2020d; Wu et al., 2020c
CA1	Blocks interaction of RBD-ACE2	SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Shi et al., 2020
CB6	Blocks interaction of RBD-ACE2	SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Shi et al., 2020
BD-368-2	Overlaps with the ACE2 binding site	SARS-CoV-2	SARS-CoV-2	N.A.	N.A.	Cao Y. et al., 2020
LY-CoV555	Blocks interaction of RBD-ACE2	SARS-CoV-2	SARS-CoV-2	NCT04427501	US FDA	Jones et al., 2020
REGN-COV2(REGN10933 +REGN10987)	Non-competitively bind RBD	SARS-CoV-2	SARS-CoV-2	NCT04425629 NCT04426695 NCT04452318	US FDA	Weinreich et al., 2021
JMB2002	Blocks interaction of RBD-ACE2	SARS-CoV-2	SARS-CoV-2	FDA approved for clinical trial	N/S	Gu et al., 2021